937263-41-7

Basic information

• Product Name: Imidazo[1,2-a]pyridine, 7-(2-methyl-4-nitrophenoxy)-
• CAS NO: 937263-41-7
• Molecular Formula: C14H11N3O3
• Molecular Weight: 269.26
• Mol File: 937263-41-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Imidazo[1,2-a]pyridine, 7-(2-methyl-4-nitrophenoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[1,2-a]pyridine, 7-(2-methyl-4-nitrophenoxy)-(937263-41-7)
• EPA Substance Registry System: Imidazo[1,2-a]pyridine, 7-(2-methyl-4-nitrophenoxy)-(937263-41-7)

Safety Data

• Hazardous Substances Data: 937263-41-7(Hazardous Substances Data)

Upstream product

• 455-88-9 5-nitro-2-fluorotoluene 
• 33631-05-9 2-amino-4-hydroxypyridine 
• 107-20-0 2-chloroethanal 
• 864244-98-4 4-(2-methyl-4-nitrophenoxy)pyridin-2-amine 

Downstream Products

• 937263-42-8 4-(imidazo[1,2-a]pyridin-7-yloxy)-3-methylaniline 

Relevant articles and documents

[1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS

The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I), wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION

A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target. (I)

Processes and intermediates for the preparation of N4-phenyl-quinazoline-4-amine derivatives

This invention provides compounds of Formula (I), wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.